keyword
MENU ▼
Read by QxMD icon Read
search

Direct antiviral agents

keyword
https://www.readbyqxmd.com/read/28423231/direct-acting-antiviral-therapy-decreases-hepatocellular-carcinoma-recurrence-rate-in-cirrhotic-patients-with-chronic-hepatitis-c
#1
Victor Virlogeux, Pierre Pradat, Kerstin Hartig-Lavie, François Bailly, Marianne Maynard, Guillaume Ouziel, Domitille Poinsot, Fanny Lebossé, Marie Ecochard, Sylvie Radenne, Samir Benmakhlouf, Joseph Koffi, Philippe Lack, Caroline Scholtes, Anne-Claire Uhres, Christian Ducerf, Jean-Yves Mabrut, Agnès Rode, Massimo Levrero, Christophe Combet, Philippe Merle, Fabien Zoulim
BACKGROUND AND AIMS: Arrival of direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) with high-sustained virological response (SVR) rates and very few side effects has drastically changed the management of HCV infection. The impact of DAA exposure on hepatocellular carcinoma (HCC) recurrence after a first remission in patients with advanced fibrosis remains to be clarified. METHODS: 68 consecutive HCV patients with a first HCC diagnosis and under remission, subsequently treated or not with a DAA combination, were included...
April 19, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28422376/spontaneous-remission-of-hepatitis-b-virus-reactivation-during-direct-acting-antiviral-agent-based-therapy-for-chronic-hepatitis-c
#2
Ken Sato, Takeshi Kobayashi, Yuichi Yamazaki, Satoshi Takakusagi, Norio Horiguchi, Satoru Kakizaki, Motoyasu Kusano, Masanobu Yamada
The administration of direct-acting antiviral agents (DAAs) to treat hepatitis C virus (HCV) infection has been reported to cause hepatitis B virus (HBV) reactivation. However, the actual conditions of HBV reactivation and the ideal timing of medical intervention have not been fully evaluated. We reported the cases of two female patients dually infected with HBV and HCV. Both patients were inactive HBV carriers. Although the serum HCV RNA levels promptly decreased after the initiation of DAA-based therapy, the serum HBV DNA levels gradually increased during DAA-based therapy, with the peak serum HBV DNA levels observed at 16 weeks after the initiation of DAA-based therapy in both cases...
April 19, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28421422/hepatitis-c-virus-genotype-3-update-on-current-and-emergent-therapeutic-interventions
#3
REVIEW
Steven W Johnson, Dorothea K Thompson, Brianne Raccor
PURPOSE OF REVIEW: Direct-acting antiviral agents (DAAs) have markedly improved the prognosis of hepatitis C virus (HCV)-genotype 3 (GT3), a highly prevalent infection worldwide. However, in patients with hepatic fibrosis, cirrhosis, or hepatocellular carcinoma (HCC), GT3 infection presents a treatment challenge compared with other genotypes. The dependence of the HCV life cycle on host lipid metabolism suggests the possible utility of targeting host cellular factors for combination anti-HCV therapy...
June 2017: Current Infectious Disease Reports
https://www.readbyqxmd.com/read/28421366/two-deletion-variants-of-middle-east-respiratory-syndrome-coronavirus-found-in-a-patient-with-characteristic-symptoms
#4
Qian Xie, Yujuan Cao, Juan Su, Jie Wu, Xianbo Wu, Chengsong Wan, Mingliang He, Changwen Ke, Bao Zhang, Wei Zhao
Significant sequence variation of Middle East respiratory syndrome coronavirus (MERS CoV) has never been detected since it was first reported in 2012. A MERS patient came from Korea to China in late May 2015. The patient was 44 years old and had symptoms including high fever, dry cough with a little phlegm, and shortness of breath, which are roughly consistent with those associated with MERS, and had had close contact with individuals with confirmed cases of MERS.After one month of therapy with antiviral, anti-infection, and immune-enhancing agents, the patient recovered in the hospital and was discharged...
April 18, 2017: Archives of Virology
https://www.readbyqxmd.com/read/28420944/new-therapies-for-hepatitis-c-virus-infection
#5
Jennifer L Horsley-Silva, Hugo E Vargas
Approximately 350 million people worldwide are infected with hepatitis C virus (HCV), which is associated with morbidity and mortality related to cirrhosis, hepatocellular carcinoma, or liver failure. Recently, vast improvements have been made with the development of direct-acting antiviral (DAA) agents, which are all-oral, are better tolerated than interferon-based treatment, and provide a sustained virologic response in more than 90% of treated patients. This article reviews the new therapies available for HCV infection, with a focus on patients who have chronic HCV with and without compensated cirrhosis...
January 2017: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28416549/antiviral-activity-and-resistance-analysis-of-ns3-4a-protease-inhibitor-grazoprevir-and-ns5a-inhibitor-elbasvir-in-hepatitis-c-virus-gt4-replicons
#6
Ernest Asante-Appiah, Stephanie Curry, Patricia McMonagle, Paul Ingravallo, Robert Chase, David Nickle, Ping Qiu, Anita Howe, Frederick C Lahser
Although genotype (GT) 4-infected patients represent a minor overall percentage of the global hepatitis C virus (HCV)-infected population, the high prevalence of the genotype in specific geographic regions coupled with substantial sequence diversity makes it an important genotype to study for antiviral drug discovery and development. We evaluated two direct-acting antiviral agents: grazoprevir, an HCV NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, in GT4 replicons prior to clinical studies in this genotype...
April 17, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28415864/-extrahepatic-manifestations-in-chronic-hepatitis-c-infected-patients
#7
Krisztina Hagymási, Anna Egresi, Gabriella Lengyel
The importance of chronic hepatitis C infection is significant. 3% of the World's population is infected. There is at least one extrahepatic manifestation in 50% of HCV patients, which makes the prognosis and mortality worse. The pathomechanisms included are cryoglobulin production, immunmechanisms, and direct viral effects. The authors summarize the main extrahepatic manifestations, as well as treatment possibilities. The aim is to draw attention to this colourful infection in order to improve the recognition in the era of the new effective direct antiviral agents...
April 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28410351/viral-dynamics-among-hepatitis-c-virus-chronic-infected-patients-during-direct-acting-antiviral-agents-therapy-impact-for-monitoring-and-optimizing-treatment-duration
#8
Andres Tabernilla, Marta Grandal, Berta Pernas, Angeles Castro-Iglesias, Iria Rodríguez-Osorio, Alvaro Mena, Manuel Delgado, Purificacion Cid, Jose D Pedreira, Eva Poveda
OBJECTIVES: Direct-acting antiviral agents (DAAs) have provided an ultimate treatment duration of 12 weeks for most hepatitis C virus (HCV)-infected patients. The opportunity to reduce treatment duration to 6 or 8 weeks is being evaluated. Here, the HCV viral dynamics at short times during HCV therapies and its implications for monitoring and optimizing treatment duration have been assessed. PATIENTS AND METHODS: HCV chronic infected patients who began HCV therapy (March 2014 to June 2015) at a reference hospital of the Northwest of Spain were selected...
April 13, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28405170/hepatitis-c-virus-pharmacogenomics-in-latin-american-populations-implications-in-the-era-of-direct-acting-antivirals
#9
REVIEW
Julieta Trinks, Mariela Caputo, María L Hulaniuk, Daniel Corach, Diego Flichman
In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because their use may lead to excellent cure rates with fewer side effects. In Latin America, the high prevalence of HCV genotype 1 infection and the significant association of Native American ancestry with risk predictive single-nucleotide polymorphisms (SNPs) in IFNL4 and ITPA genes highlight the need to implement new treatment regimens in these populations...
2017: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/28404073/optimum-timing-of-treatment-for-hepatitis-c-infection-relative-to-liver-transplantation
#10
REVIEW
Audrey Coilly, Bruno Roche, Jean-Charles Duclos-Vallée, Didier Samuel
The approval of direct-acting antiviral agents that may be given orally in an interferon-free regimen has greatly changed the landscape of treatment for hepatitis C virus (HCV) infection, especially for patients with the most severe disease, who have decompensated cirrhosis, or who are waiting for or have undergone liver transplantation. Treatment with interferon proved to be ineffective and poorly tolerated because of high risks of infection and transplant rejection. The availability of new drugs poses new questions about the optimum time to give treatment to prevent HCV recurrence, taking into account efficacy, tolerance, and drug-drug interactions...
October 2016: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28401658/kreuth-iv-european-consensus-proposals-for-treatment-of-haemophilia-with-coagulation-factor-concentrates
#11
P L F Giangrande, F Peyvandi, B O'Mahony, M-E Behr-Gross, A Hilger, W Schramm, P M Mannucci
INTRODUCTION: This report summarizes recommendations relating to haemophilia therapy arising from discussions among experts from 36 European countries during the 'Kreuth IV' meeting in May 2016. AIM: The objective of the meeting was for experts in the field of haemophilia from across Europe to draft resolutions regarding current issues relating to the treatment of haemophilia. RESULTS: Hospitals providing clinical care for people with haemophilia and related disorders are strongly recommended to seek formal designation as either European Haemophilia Treatment Centres (EHTC) or European Haemophilia Comprehensive Care Centres (EHCCC)...
April 12, 2017: Haemophilia: the Official Journal of the World Federation of Hemophilia
https://www.readbyqxmd.com/read/28401125/drug-therapies-for-chronic-hepatitis-c-infection-a-cost-effectiveness-analysis
#12
William W L Wong, Karen M Lee, Sumeet Singh, George Wells, Jordan J Feld, Murray Krahn
BACKGROUND: Before 2011, pegylated interferon plus ribavirin was the standard therapy for chronic hepatitis C. Interferon-free direct-acting antiviral agents were then approved. Although these treatments appear to be more effective, they are substantially more expensive. In anticipation of the need for information regarding the comparative cost-effectiveness of new regimens in a recent therapeutic review, we conducted the analysis to inform listing decision in Canada. METHODS: A state-transition model was developed in the form of a cost-utility analysis...
January 2017: CMAJ Open
https://www.readbyqxmd.com/read/28399806/current-challenges-and-possible-solutions-to-improve-access-to-care-and-treatment-for-hepatitis-c-infection-in-vietnam-a-systematic-review
#13
Alessandra Berto, Jeremy Day, Nguyen Van Vinh Chau, Guy E Thwaites, Ngoc Nghiem My, Stephen Baker, Thomas C Darton
BACKGROUND: Hepatitis C infection is a major public health concern in low- and middle-income countries where an estimated 71.1 million individuals are living with chronic infection. The World Health Organization (WHO) has recently released new guidance for hepatitis C virus (HCV) treatment programs, which include improving the access to new direct-acting antiviral agents. In Vietnam, a highly populated middle-income country, the seroprevalence of HCV infection is approximately 4% and multiple genotypes co-circulate in the general population...
April 11, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28390869/efficacy-of-8-weeks-of-sofosbuvir-velpatasvir-and-voxilaprevir-in-patients-with-chronic-hcv-infection-2-phase-3-randomized-trials
#14
Ira M Jacobson, Eric Lawitz, Edward J Gane, Bernard E Willems, Peter J Ruane, Ronald G Nahass, Sergio M Borgia, Stephen D Shafran, Kimberly A Workowski, Brian Pearlman, Robert H Hyland, Luisa M Stamm, Evguenia Svarovskaia, Hadas Dvory-Sobol, Yanni Zhu, G Mani Subramanian, Diana M Brainard, John G McHutchison, Norbert Bräu, Thomas Berg, Kosh Agarwal, Bal Raj Bhandari, Mitchell Davis, Jordan J Feld, Gregory J Dore, Catherine A M Stedman, Alexander J Thompson, Tarik Asselah, Stuart K Roberts, Graham R Foster
BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) following 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir. We assessed the efficacy of 8 weeks of treatment with sofosbuvir and velpatasvir plus the pangenotypic NS3/4A protease inhibitor voxilaprevir (sofosbuvir-velpatasvir-voxilaprevir). METHODS: In 2 phase 3, open-label trials, patients with HCV infection who had not previously been treated with a direct-acting antiviral agent were randomly assigned to groups given sofosbuvir-velpatasvir-voxilaprevir for 8 weeks or sofosbuvir-velpatasvir for 12 weeks...
April 5, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28389143/identification-of-treatment-experienced-hepatitis-c-patients-with-poor-cost-effectiveness-of-pegylated-interferon-plus-ribavirin-from-a-real-world-cohort
#15
Ta-Wei Liu, Pei-Chien Tsai, Ching-I Huang, Yi-Shan Tsai, Shu-Chi Wang, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Nai-Jen Hou, Chung-Feng Huang, Ming-Lun Yeh, Zu-Yau Lin, Shinn-Cherng Chen, Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, Ming-Lung Yu
BACKGROUND/PURPOSE: Pegylated interferon (PegIFN) plus ribavirin (RBV) combination therapy has been the standard of care since 2002. Although a better viral response has been achieved among chronic hepatitis C (CHC) patients in Taiwan, approximately 25% of hepatitis C virus (HCV) genotype 1 (G1) patients and 15% of G2 patients failed to achieve a sustained virological response (SVR) at the first therapy. The actual cost-effectiveness of the retreatment remains elusive. The present study conducted a real-world cost-effectiveness analysis of a large cohort among different pre-specified subgroups of treatment-experienced CHC patients...
April 4, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/28388935/direct-acting-antiviral-agents-in-the-therapy-of-hepatitis-c-virus-related-mixed-cryoglobulinaemia-a-single-centre-experience
#16
Gianfranco Lauletta, Sabino Russi, Fabio Pavone, Angelo Vacca, Franco Dammacco
BACKGROUND: The efficacy and safety of direct-acting antiviral agents (DAAs) were evaluated in a cohort of prospectively enrolled patients with hepatitis C virus (HCV)-related mixed cryoglobulinaemia (MC), an immune complex-mediated vasculitis of small and medium vessels in which the pathogenetic role of HCV has been clearly established. METHODS: Twenty-two patients received DAAs. Clinical and laboratory features were recorded at baseline, every 4 weeks until the end of treatment (EoT), and 12 weeks afterwards...
April 8, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28388736/liver-cancer-emergence-associated-with-antiviral-treatment-an-immune-surveillance-failure
#17
María Reig, Loreto Boix, Zoe Mariño, Ferran Torres, Xavier Forns, Jordi Bruix
The availability of new direct antiviral agents to safely and effectively treat the hepatitis C virus represents a major advancement in the field of liver disease. Most patients achieve complete viral eradication sustained over time. In addition, the administration of these new agents is safe and does not require limitations when liver function is impaired. Some now expect the hepatitis C virus to be completely eradicated in a few years. However, not all data are positive. In April 2016, we published a cohort study suggesting that viral eradication with the new agents could be associated in time with the emergence of recurrent cancer sites in patients previously treated for hepatocellular carcinoma...
April 7, 2017: Seminars in Liver Disease
https://www.readbyqxmd.com/read/28386819/disease-burden-early-discontinuation-and-healthcare-costs-in-hepatitis-c-patients-with-and-without-chronic-kidney-disease-treated-with-interferon-free-direct-acting-antiviral-regimens
#18
Amy Puenpatom, Michael Hull, Jeffrey McPheeters, Kay Schwebke
BACKGROUND: Hepatitis C virus (HCV) is a risk factor for chronic kidney disease (CKD) and end-stage renal disease (ESRD). Direct-acting antiviral agents (DAAs) have improved HCV management in CKD patients, however real-world clinical practice data are limited. OBJECTIVE: This study examined the prevalence of CKD among HCV patients receiving oral DAAs in a real-world setting. Comorbidities, early discontinuation rates, and healthcare costs were compared between patients with and without CKD...
April 6, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28383274/past-current-and-future-developments-of-therapeutic-agents-for-treatment-of-chronic-hepatitis-b-virus-infection
#19
Yameng Pei, Chunting Wang, S Frank Yan, Gang Liu
For decades, treatment of hepatitis B virus (HBV) infection has been relying on interferon (IFN)-based therapies and nucleoside/nucleotide analogues (NAs) that selectively target the viral polymerase reverse transcriptase (RT) domain and thereby disrupt HBV viral DNA synthesis. We have summarized here the key steps in the HBV viral life cycle, which could potentially be targeted by novel anti-HBV therapeutics. A wide range of next-generation direct antiviral agents (DAAs) with distinct mechanisms of actions are discussed, including entry inhibitors, transcription inhibitors, nucleoside/nucleotide analogues, inhibitors of viral ribonuclease H (RNase H), modulators of viral capsid assembly, inhibitors of HBV surface antigen (HBsAg) secretion, RNA interference (RNAi) gene silencers, antisense oligonucleotides (ASOs), and natural products...
April 21, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28379589/toxicity-and-risks-from-drug-to-drug-interactions-of-new-antivirals-for-chronic-hepatitis-c
#20
C Binda, A Tortora, M Garcovich, B E Annicchiarico, M Siciliano
The new direct acting antivirals (DAAs), defined as those drugs that are effective in combinations without interferon, have totally changed HCV treatment and probably in few years will also totally change global landscape of advanced liver diseases. The advantage of DAAs is a low-risk/high-benefit ratio. Although overall adverse events during DAAs treatment are limited in frequency and severity, some toxicity issues emerged during the first years of real-life experience with these drugs. Another peculiar characteristic of present DAAs is a high probability of interaction with other "common-use" drugs, such as anti-hypertensive, anti-platelet, antiarrhythmic and cholesterol lowering agents...
March 2017: European Review for Medical and Pharmacological Sciences
keyword
keyword
12534
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"